同期，公司国际化战略实现关键突破，海外市场拓展全面提速。截至2025年底，公司销售渠道已覆盖全 球83个国家与地区，并与超过80家海外合作伙伴建立战略合作关系。2026年1月，公司宣布战略收购德 国Optimed公司，进一步拓展在欧洲及全球市场的布局，加快创新产品在国际市场的推广与落地；同时 依托中、德两大生产基地之间的协同效应，持续提升全球化运营与交付能力。 归创通桥表示，2025年公司业绩表现亮眼，主要受益于核心产品销售的强劲增长、海外业务的加速发展 以及运营效率的持续优化。报告期内，公司通桥麒麟™血流导向装置、神经血管导丝、UltraFree药物洗 脱PTA球囊扩张导管、ZYLOX Swan静脉腔内射频闭合导管等产品销售收入均实现较快增长。国际业务 方面，公司海外市场销售收入同比增长超过100%，在德国、法国、意大利等重点国家市场的渗透率持 续提升。 智通财经APP获悉，归创通桥(02190)盈喜后涨超5%，截至发稿，涨4.06%，报24.46港元，成交额433.55 万港元。 消息面上，1月29日，归创通桥发布2025年全年业绩正面盈利预告。公司预期2025年全年净利润超过人 民币2.4亿元，较去年同 ...

Core Viewpoint - Spring Medical (01858) has shown a significant increase in stock price and is expected to report substantial profit growth for the fiscal year 2025, indicating strong operational performance and strategic initiatives [1] Financial Performance - The company forecasts a net profit attributable to shareholders of RMB 245 million to RMB 288 million for 2025, representing an increase of RMB 120 million to RMB 163 million compared to the previous year, which is a year-on-year growth of 96.01% to 130.41% [1] - The net profit attributable to shareholders after excluding non-recurring gains and losses is expected to be between RMB 230 million and RMB 270 million, reflecting an increase of RMB 135 million to RMB 175 million year-on-year, translating to a growth of 142.80% to 185.11% [1] Strategic Initiatives - The company attributes its expected profit growth to the gradual release of growth potential across its product lines following the inclusion in centralized procurement [1] - Spring Medical is committed to an international development strategy and is steadily advancing its international business layout, which supports sustained and healthy revenue growth [1] - The company is focusing on enhancing operational management, optimizing resource allocation, and improving overall efficiency and profitability, which are crucial for supporting its performance growth [1]

Group 1 - On January 29, Botao Bio's stock fell by 2.76%, with a trading volume of 103 million yuan [1] - The financing data showed that on the same day, Botao Bio had a financing purchase amount of 10.18 million yuan and a financing repayment of 14.82 million yuan, resulting in a net financing outflow of 4.64 million yuan [1] - As of January 29, the total balance of margin trading for Botao Bio was 288 million yuan, which accounted for 5.21% of its market capitalization [1] Group 2 - As of September 30, the number of shareholders of Botao Bio was 7,146, an increase of 28% compared to the previous period [2] - For the period from January to September 2025, Botao Bio reported an operating income of 308 million yuan, a year-on-year decrease of 20.76%, and a net profit attributable to shareholders of 22.26 million yuan, down 75.04% year-on-year [2] - Since its A-share listing, Botao Bio has distributed a total of 798 million yuan in dividends, with 478 million yuan distributed in the last three years [2]

Group 1 - On January 29, 2023, Maipu Medical's stock fell by 3.42%, with a trading volume of 90.3 million yuan [1] - The financing data for Maipu Medical on the same day showed a financing purchase amount of 5.86 million yuan and a financing repayment of 11.41 million yuan, resulting in a net financing outflow of 5.55 million yuan [1] - As of January 29, 2023, the total balance of margin trading for Maipu Medical was 106 million yuan, which accounted for 2.34% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, 2023, Maipu Medical had 6,043 shareholders, a decrease of 2.36% from the previous period, while the average circulating shares per person increased by 2.52% to 9,272 shares [2] - For the period from January to September 2023, Maipu Medical achieved an operating income of 249 million yuan, representing a year-on-year growth of 30.53%, and a net profit attributable to shareholders of 75.85 million yuan, up 43.65% year-on-year [2] Group 3 - Since its A-share listing, Maipu Medical has distributed a total of 85.80 million yuan in dividends, with 79.20 million yuan distributed over the past three years [3] - As of September 30, 2023, the Southern Medical Health Flexible Allocation Mixed A Fund (000452) has exited the top ten circulating shareholders of Maipu Medical [3]

截至9月30日，康拓医疗股东户数5879.00，较上期增加15.30%；人均流通股13818股，较上期减少 13.27%。2025年1月-9月，康拓医疗实现营业收入2.51亿元，同比增长4.57%；归母净利润7671.52万元， 同比增长0.00%。 分红方面，康拓医疗A股上市后累计派现1.68亿元。近三年，累计派现1.02亿元。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 融资方面，康拓医疗当日融资买入479.48万元。当前融资余额9024.47万元，占流通市值的2.99%，融资 余额超过近一年50%分位水平，处于较高位。 融券方面，康拓医疗1月29日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，西安康拓医疗技术股份有限公司位于陕西省西安市高新区毕原一路西段1451号，成立日期 2005年 ...

Group 1 - On January 29, Aojing Medical experienced a decline of 3.34% with a transaction volume of 86.96 million yuan, and the net financing buy was -45,500 yuan [1] - As of January 29, the total margin balance for Aojing Medical was 225 million yuan, accounting for 7.09% of its circulating market value, indicating a high level compared to the past year [1] - The company specializes in high-end biomedical materials and related medical device products, with its main revenue sources being 骼金 (74.91%), 颅瑞 (16.35%), and others [1] Group 2 - As of September 30, Aojing Medical had 9,862 shareholders, an increase of 15.44%, while the average circulating shares per person decreased by 13.37% [2] - For the period from January to September 2025, Aojing Medical reported a revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% year-on-year [2] - The company has distributed a total of 58.67 million yuan in dividends since its A-share listing, with 22.40 million yuan distributed in the last three years [3]

Core Insights - Boston Scientific has completed the acquisition of Nalu Medical for approximately $600 million in cash, which includes the purchase of remaining shares after previously holding a strategic investment since 2017 [2][6] - Nalu Medical specializes in spinal and peripheral nerve stimulation technologies aimed at chronic neuropathic pain patients, utilizing low-intensity electrical pulses to modulate pain signals before they reach the brain [5][6] - The acquisition is part of Boston Scientific's broader strategy to enhance its portfolio in interventional therapy and pain management, following a series of significant acquisitions in recent years [7][9] Nalu Medical's Product Technology and Business Expectations - Nalu's peripheral nerve stimulation system received FDA approval in 2019 and was further approved for full-body MRI scans in 2025, indicating regulatory progress [6] - The company introduced a miniaturized wearable external power source and completed a $50 million growth funding round in 2025 [6] - Nalu is expected to generate over $60 million in revenue in 2025, with a projected year-on-year growth of over 25% in 2026 [6] Financial Impact and Strategic Positioning - The acquisition is anticipated to have a minimal impact on adjusted earnings per share in 2026, with a gradual positive effect starting in 2027, although there may be short-term dilution on GAAP earnings due to amortization and acquisition-related expenses [6] - Boston Scientific's recent acquisitions, including a $14.5 billion deal for Penumbra and others, reflect a strategic focus on expanding capabilities in interventional treatment and nerve modulation [7][11] Industry Background - The acquisition of Nalu Medical aligns with Boston Scientific's ongoing efforts to strengthen its position in the chronic pain treatment and minimally invasive intervention sectors, which are critical areas of development in the medical technology industry [9][13] - Nalu's innovative features, such as a battery-free micro-implantable pulse generator and smartphone-based treatment control, highlight advancements in pain management technology [10]

Core Viewpoint - Lepu Medical (300003.SZ) has reversed its declining performance, projecting significant growth in its 2025 annual results, with expected net profit ranging from 800 million to 1.2 billion yuan, representing a year-on-year increase of 223.97% to 385.95% [1][2] Financial Performance - For 2025, Lepu Medical anticipates both net profit and non-net profit to be between 800 million and 1.2 billion yuan, with median estimates indicating a growth of approximately 304.86% and 352.49% compared to the previous year [2] - The company experienced a decline in revenue and net profit in 2023 and 2024, with net profit dropping by 42.91% and 80.37% respectively [3][4] Business Segments - The core business of cardiovascular interventional devices has shown stable revenue growth, while the pharmaceutical segment has achieved double-digit growth due to the completion of inventory clearance in retail channels [5] - Strategic emerging sectors, including innovative drugs and dermatology, have contributed to the performance increase [5] Research and Development - Lepu Medical has consistently invested over 1 billion yuan annually in R&D, with total R&D expenditures from 2021 to 2024 being 11.12 billion, 12.84 billion, 12.42 billion, and 11.65 billion yuan respectively [7] - The company has developed several "firsts" in domestic medical technology, including bioabsorbable stents and dual-chamber cardiac pacemakers, establishing a strong competitive edge in the cardiovascular field [7] Financial Health - As of September 2025, the company's debt-to-asset ratio is approximately 30.71%, indicating a solid financial position [8] - Lepu Medical's operating cash flow has consistently shown net inflows, with a projected year-on-year increase of about 95% for 2025 [8]

Core Viewpoint - Yirui Technology (688301.SH), a manufacturer of digital X-ray detectors, achieved record high performance in 2025, with significant revenue and profit growth driven by stable growth in its digital X-ray detector business and substantial growth in comprehensive solutions and core components [2][4]. Financial Performance - In 2025, the company reported revenue of 2.299 billion yuan, a year-on-year increase of 25.53% - The net profit attributable to shareholders reached 661 million yuan, up 42.15% - The net profit after deducting non-recurring gains and losses was 627 million yuan, reflecting a growth of 42.89% [2][4]. Market Position - Yirui Technology holds a leading position in the global market for digital X-ray detectors, with a market share of 19.83% in 2024, up from 16.46% in 2021 [3]. - The company has consistently ranked first in market share within China for digital X-ray detectors [3]. Employee Incentives - The company is implementing a multi-tiered incentive system to enhance talent development and bind the core team, promoting long-term growth [6]. - A 2026 employee stock ownership plan has been proposed, with an initial cap of 150 participants and a funding limit of 100 million yuan, linked to performance targets based on 2025 net profit [6][7]. Strategic Investments - In October 2025, Yirui Technology raised 1.16 billion yuan through a private placement to fund projects related to X-ray vacuum devices and comprehensive solutions [5]. - The total assets of the company reached 12.79 billion yuan by the end of 2025, a 40.81% increase from the previous year [5]. Subsidiary Development - Yirui Hefei, a wholly-owned subsidiary, is set to introduce strategic investors through a 500 million yuan capital increase, enhancing its financial strength and operational scale [8][9]. - The introduction of local state-owned investors is expected to deepen strategic cooperation and improve the subsidiary's market competitiveness [8].

开展企业动员暨培训，筑牢新规落地根基。要求各级监管部门对辖区内企业开展新版《规范》落地 动员暨首轮培训，为企业自查整改和后续合规生产奠定基础。全面自查自纠，夯实企业主体责任。要求 各生产企业对照新版《规范》全面排查质量管理体系存在的差距和不足，制定整改方案并完成整改，确 保合规生产。全面组织宣传培训，提升监管效能。要求各级监管部门构建分层分类的监管人员培训体 系。强化宣贯引导，护航新规落地。要求各级监管部门做好宣传引导和配套保障工作，健全检查衔接机 制，确保上市前后监管标准统一；将新版《规范》落实情况纳入日常监管重点内容，形成监管合力。 为深入贯彻落实国家药监局关于全面推动新版《医疗器械生产质量管理规范》，近日，省药监局印 发《河南省药品监督管理局贯彻落实新版〈医疗器械生产质量管理规范〉实施方案》，围绕"强化企业 主体责任、提升监管履职能力、完善落地保障机制"核心要求，系统部署4个方面共计13项具体工作任 务，确保新版《规范》在我省顺利实施。 ...